Next Generation Multiplex Assay Platform for Respiratory Pathogen Detection
27 Apr 2016
Watch this video to see how Luminex’s next generation NxTAG® Respiratory Pathogen Panel, a highly multiplexed assay platform, allows the user to test a single sample to detect up to 21 different pathogens all in a single well. The panel has a high throughput capability of up to 96 reactions per run to simplify workflow and so reduces hands-on time required.
For more information about the Luminex NxTAG® Respiratory Pathogen Panel click here.
About the company
Luminex
Luminex Corporation develops, manufactures, and sells proprietary technology, assays, and systems that empower labs to obtain reliable, timely, and actionable answers, ultimately advancing health. Our Molecular Diagnostics (MDx) and Life Science and Clinical Tools portfolios provide cost-effective, flexible solutions for hospitals, reference labs, and researchers, as well as innovative xMAP® and flow cytometry solutions that span a wide variety of applications, including molecular diagnostics, drug discovery, life science research, immunology, personalized medicine, cellular analysis, and more. Our goal is to transform global healthcare with innovative technology that delivers rapid, reliable results to clinicians and researchers. Most recently, we have been actively focused on providing diagnostic tests for SARS-CoV-2, with two diagnostic tests currently on the market. We are also pursuing several additional options in serology testing. For further information, please visit luminexcorp.com/.
